• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HLA-B*4402和-B*4403天然肽配体的表征:肽参与HLA-B44重链单个氨基酸变化的同种异体识别的意义。

Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain.

作者信息

Fleischhauer K, Avila D, Vilbois F, Traversari C, Bordignon C, Wallny H J

机构信息

Department of Biology and Biotechnology (DIBIT), Istituto Scientifico H.S. Raffaele, Milano, Italy.

出版信息

Tissue Antigens. 1994 Nov;44(5):311-7. doi: 10.1111/j.1399-0039.1994.tb02401.x.

DOI:10.1111/j.1399-0039.1994.tb02401.x
PMID:7878657
Abstract

This study describes the characterization of endogenous peptides associated with the two major subtypes of HLA-B44. The two subtypes differ for a single amino acid substitution from Asp (HLA-B4402) to Leu (HLA-B4403) in position 156 of the alpha 2 domain, causing strong alloreactivity in vivo. In order to study the involvement of peptides in this phenomenon, the peptide motifs of the two subtypes were determined from natural peptide pools using Edman degradation. The motif was found to be essentially identical for HLA-B4402 and -B4403, with a strong predominance for Glu at position 2, Tyr or Phe at positions 9 and 10 and hydrophobic residues, especially Met, at position 3. Two individual naturally processed ligands of HLA-B4403 were sequenced and shown to be derived from intracellularly expressed proteins found in protein sequence databases. The sequence of these natural peptide ligands conform well to the determined motif. These data will allow the prediction of HLA-B44 restricted peptide epitopes from viral and tumor antigens of known amino acid sequences. Moreover, they indicate that the peptide repertoire presented by HLA-B4402 and -B*4403 is very similar, suggesting that the strong alloresponse between these two subtypes is not due to presentation of a different set of self peptides.

摘要

本研究描述了与HLA - B44的两种主要亚型相关的内源性肽的特征。这两种亚型在α2结构域第156位存在单个氨基酸取代差异,从天冬氨酸(HLA - B4402)变为亮氨酸(HLA - B4403),在体内引起强烈的同种异体反应性。为了研究肽在这一现象中的作用,利用埃德曼降解法从天然肽库中确定了这两种亚型的肽基序。发现HLA - B4402和 - B4403的基序基本相同,第2位强烈偏好谷氨酸,第9和10位为酪氨酸或苯丙氨酸,第3位为疏水残基,尤其是甲硫氨酸。对HLA - B4403的两个天然加工配体进行了测序,结果表明它们源自蛋白质序列数据库中细胞内表达的蛋白质。这些天然肽配体的序列与确定的基序非常吻合。这些数据将有助于从已知氨基酸序列的病毒和肿瘤抗原中预测HLA - B44限制性肽表位。此外,这些数据表明HLA - B4402和 - B*4403所呈递的肽库非常相似,这表明这两种亚型之间强烈的同种异体反应不是由于呈递了不同的自身肽组。

相似文献

1
Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain.HLA-B*4402和-B*4403天然肽配体的表征:肽参与HLA-B44重链单个氨基酸变化的同种异体识别的意义。
Tissue Antigens. 1994 Nov;44(5):311-7. doi: 10.1111/j.1399-0039.1994.tb02401.x.
2
Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid.细胞毒性T淋巴细胞(CTL)对由HLA - B*4402和HLA - B*4403分子呈递的肽段的识别存在差异,这两种分子仅相差一个氨基酸。
Tissue Antigens. 1999 Feb;53(2):111-21. doi: 10.1034/j.1399-0039.1999.530201.x.
3
Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population.鉴定HLA - B44的肽结合基序,HLA - B44是白种人群中最常见的HLA - B等位基因之一。
Biochemistry. 1995 Aug 15;34(32):10130-8. doi: 10.1021/bi00032a005.
4
Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.在表达MAGE-3基因的肿瘤细胞上由HLA-B44分子呈递的抗原肽的鉴定
Int J Cancer. 1996 Nov 27;68(5):622-8. doi: 10.1002/(SICI)1097-0215(19961127)68:5<622::AID-IJC12>3.0.CO;2-3.
5
Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex.鉴定与三种HLA B44等位基因结合的显性自身配体以及每种复合物重组形式的初步晶体学分析。
FEBS Lett. 2002 Sep 11;527(1-3):27-32. doi: 10.1016/s0014-5793(02)03149-6.
6
Alpha-2 domain polymorphism and HLA class I peptide loading.α-2结构域多态性与HLA I类分子的肽负载
Tissue Antigens. 1999 Nov;54(5):450-60. doi: 10.1034/j.1399-0039.1999.540502.x.
7
Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells.野生型p53表位在人乳腺癌细胞上由HLA - B单倍型自然加工并呈递。
Clin Cancer Res. 1999 Aug;5(8):2089-93.
8
Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability.HLA - B*2705和B*2709与强直性脊柱炎的差异关联与有限的肽亚群相关,但与细胞表面稳定性改变无关。
J Biol Chem. 2002 Aug 9;277(32):28749-56. doi: 10.1074/jbc.M204155200. Epub 2002 May 31.
9
Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype.HLA B44超型多个分子结合能力的同步预测
J Immunol. 2003 Dec 1;171(11):5964-74. doi: 10.4049/jimmunol.171.11.5964.
10
HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44.HLA光亲和标记揭示了同源黑色素瘤相关基因肽与HLA - A1、HLA - A29和HLA - B44的重叠结合。
J Biol Chem. 1996 May 24;271(21):12463-71. doi: 10.1074/jbc.271.21.12463.

引用本文的文献

1
Purification of HLA Immunopeptidomes from Human Thymus.从人胸腺中纯化 HLA 免疫肽组。
Methods Mol Biol. 2022;2420:127-136. doi: 10.1007/978-1-0716-1936-0_10.
2
The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing.与白塞病相关的氨肽酶ERAP1变体通过差异亚肽组加工形成低亲和力的HLA - B*51肽组。
J Biol Chem. 2017 Jun 9;292(23):9680-9689. doi: 10.1074/jbc.M117.789180. Epub 2017 Apr 26.
3
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
癌症免疫疗法和精准医学的免疫靶点与新抗原
Cell Res. 2017 Jan;27(1):11-37. doi: 10.1038/cr.2016.155. Epub 2016 Dec 27.
4
Cross-Reactivity of TCR Repertoire: Current Concepts, Challenges, and Implication for Allotransplantation.TCR 库的交叉反应性:当前概念、挑战及对同种异体移植的意义
Front Immunol. 2016 Mar 24;7:89. doi: 10.3389/fimmu.2016.00089. eCollection 2016.
5
Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes.了解HLA - B*35亚型中第156位残基处的不相容障碍。
Immunogenetics. 2016 Apr;68(4):247-60. doi: 10.1007/s00251-015-0896-4. Epub 2016 Jan 12.
6
Selector function of MHC I molecules is determined by protein plasticity.MHC I 分子的选择功能由蛋白质可塑性决定。
Sci Rep. 2015 Oct 20;5:14928. doi: 10.1038/srep14928.
7
Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.可溶性 HLA 技术作为评估 HLA 错配影响的策略。
J Immunol Res. 2014;2014:246171. doi: 10.1155/2014/246171. Epub 2014 Sep 1.
8
Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.Nef 特异性 CD8+ T 细胞应答有助于 HIV-1 的免疫控制。
PLoS One. 2013 Sep 2;8(9):e73117. doi: 10.1371/journal.pone.0073117. eCollection 2013.
9
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.通过细胞穿透肽的细胞内递送和模式识别受体信号的刺激来增强癌症免疫疗法。
Adv Immunol. 2012;114:151-76. doi: 10.1016/B978-0-12-396548-6.00006-8.
10
TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.T 细胞受体交叉反应性和同种异体识别:同种异体识别免疫遗传学的新见解。
Immunogenetics. 2012 Feb;64(2):77-85. doi: 10.1007/s00251-011-0590-0. Epub 2011 Dec 3.